The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis

Abstract

Purpose Trastuzumab, a potent anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, is conditionally reimbursed by the Taiwan National Health Insurance (NHI) for HER2-positive breast cancer (BC). Trastuzumab-induced cardiotoxicity studies have well characterized heart failure (HF) but fewer addressed arrhythmia, particularly the association of potential life threatening atrial fibrillation (Af) is poorly characterized. We aimed to study the trastuzumab-related risk of Af and HF using the claimed data of Taiwan NHI. Methods A nationwide retrospective cohort of patients with BC from the Taiwan NHI reimbursement database from January 2007 to December 2016 was analyzed. Propensity score matching and competing risk model analysis were used for adjusting confounding concurrent medication or comorbidities and competing events. The HF study was used to validate the method used. Results For Af, 12,472 trastuzumab users were matched with 12,472 non-trastuzumab users. For HF, 12,241 trastuzumab users and 12,241 non-users were enrolled. We found that trastuzumab users had significantly worse HF-free survival but not Af-free survival than non-trastuzumab users. In the competing risk analysis, the use of trastuzumab did not increase the risk of Af (hazard ratio [HR] 0.76, P = 0.0006) but was associated with HF (HR 1.19, P = 0.0052). The risk trends among stratifications by comorbidities and concurrent medication remained in similar directions for both Af and HF. Conclusion Trastuzumab in real-world practice was associated with an increased risk of HF, but was not associated with an increased risk of Af in BC patients. Trastuzumab-induced arrhythmogenic effects may be masked by concurrent heart-protecting measures, more prominent roles of comorbidities or concurrent medications under real-world settings. Further studies are required.

Recognizing Risk Factors of Breast Cancer Development and Evaluating the Efficacy of Mammography Screening in Taiwan

“…Supplementary Table 3 shows hazard ratios for relapse-free and overall survival: ER, PR, grade, and pathological stage were in concordance with what we expected, while HER2 status no longer represented a poor prognostic factor, which could be partially explained by the advances in anti-HER2 targeted therapy as well as the NHI's reimbursement of trastuzumab for nodal positive breast cancers [37]. Clinically detected breast cancers without a screening history were associated with compromised relapsefree and overall survival (HR:1.376 and 1.66, respectively), and this effect persisted even in competing risk breast cancer-speci c survival.…”

Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging

“…Anthracyclines, HER2-targeted therapy, and some tyrosine kinase inhibitors can be associated with QTc prolongation, and concurrent therapy with other QT prolonging medications, such as antiemetics or antibiotics, may accentuate this effect. Such patients warrant close ECG monitoring, ensuring electrolytes, particularly potassium and magnesium are replete, and a review of concurrent medications to find alternatives that may have less effect on QTc and so minimize interruption to cancer therapy [36,[46][47][48].…”

Atrial fibrillation and malignant neoplasms: state of the problem

“…В работе W.C. Wu и соавт. показано, что лечение трастузумабом связано с высоким риском развития СН (р = 0,0052), при этом увеличения риска возникновения ФП показано не было (р = 0,0006) [46].…”